Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma

Pharmaceutical Research

Volumn 33, Issue 1, 2016, Pages 137-154

  Godugu, Chandraiah ^a,b   Doddapaneni, Ravi ^a   Patel, Apurva R ^a   Singh, Rakesh ^c   Mercer, Roger ^c   Singh, Mandip ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^c FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

A431; control release formulations; epidermal growth factor receptor; gefitinib; spray drying

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CHITOSAN; GEFITINIB; HYDROXYPROPYLMETHYLCELLULOSE; SUCCINIC ACID; TOCOFERSOLAN; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; EXCIPIENT; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER SIZE; CANCER SURVIVAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LONG TERM CARE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; SKIN CARCINOMA; SPRAY DRYING; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TUMOR XENOGRAFT; TUNEL ASSAY; WESTERN BLOTTING; ANIMAL; BIOAVAILABILITY; CACO-2 CELL LINE; CARCINOMA, SQUAMOUS CELL; DRUG SCREENING; GENETICS; HUMAN; MEDICINAL CHEMISTRY; NUDE MOUSE; RAT; SKIN NEOPLASMS; SOLUBILITY; SPRAGUE DAWLEY RAT; SURVIVAL ANALYSIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; EXCIPIENTS; HUMANS; MICE, NUDE; PROTEOMICS; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; SKIN NEOPLASMS; SOLUBILITY; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84952876656     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1771-6     Document Type: Article

References (70)

1. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and prelimi nary clinical results. Invest New Drug. 1999;17(3):259-69.
2. Johnston JB, Navaratnam S, Pitz MW, Maniate JM, Wiechec E, Baust H, et al. Targeting the EGFR pathway for cancer therapy. Curr Med Chem. 2006;13(29):3483-92.
3. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002;62(20):5749-54.
4. Hara F, Aoe M, Doihara H, Taira N, Shien T, Takahashi H, et al. Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo. Cancer Lett. 2005;226(1):37-47.
5. Penne K, Bohlin C, Schneider S, Allen D. Gefitinib (Iressa (TM), ZD1839) and tyrosine kinase inhibitors - The wave of the future in cancer therapy. Cancer Nurs. 2005;28(6):481-6.
6. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 1999;82(2-3):241-50.
7. Herbst RS, Fukuoka M, Baselga J. Timeline - Gefitinib - a novel targeted approach to treating cancer. Nat Rev Cancer. 2004;4(12):956-65.
8. Djerf EA, Trinks C, Abdiu A, Thunell LK, Hallbeck AL, Walz TM. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839). Melanoma Res. 2009;19(3):156-66.
9. Chougule MB, Patel AR, Patlolla R, Jackson T, Singh M. Epithelial transport of Noscapine across cell monolayer and influence of absorption enhancers on in vitro permeation and bioavailability: implications for intestinal absorption. J Drug Target. 2014;22(6):498-508.
10. Patel AR, Chougule MB, Townley I, Patlolla R, Wang G, Singh M. Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel. Pharm Res. 2013;30(5):1435-46.
11. Chougule MB, Patel A, Sachdeva P, Jackson T, Singh M. Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer. PLoS One. 2011;6(11), e27394.
12. Patel AR, Chougule MB, Lim E, Francis KP, Safe S, Singh M. Theranostic tumor homing nanocarriers for the treatment of lung cancer. Nanomed Nanotechnol Biol Med. 2014;10(5):1053-63.
13. Patel AR, Chougule M, Singh M. EphA2 targeting pegylated nanocarrier drug delivery system for treatment of lung cancer. Pharm Res. 2014;31(10):2796-809.
14. Patel AR, Doddapaneni R, Andey T, Wilson H, Safe S, Singh M. Evaluation of Self-emulsified DIM-14 in dogs for oral bioavailability and in Nu/nu mice bearing stem cell lung tumor models for anticancer activity. J Control Release. 2015;213:18-26.
15. Andey T, Sudhakar G, Marepally S, Patel A, Banerjee R, Singh M. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation. Mol Pharm. 2015;12(4):1105-20.
16. Patel AR, Godugu C, Wilson H, Safe S, Singh M. Evaluation of spray BIO-Max DIM-P in dogs for oral bioavailability and in nu/nu mice bearing orthotopic/metastatic lung tumor models for anticancer activity. Pharm Res 1-9.
17. Trummer BJ, Iyer V, Balu-Iyer SV, O'Connor R, Straubinger RM. Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib. J Pharm Sci-Us. 2012;101(8):2763-76.
18. Lee YHP, Sathigari S, Lin YJJ, Ravis WR, Chadha G, Parsons DL, et al. Gefitinib-cyclodextrin inclusion complexes: physico-chemical characterization and dissolution studies. Drug Dev Ind Pharm. 2009;35(9):1113-20.
19. Friesen DT, Shanker R, Crew M, Smithey DT, Curatolo WJ, Nightingale JAS. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol Pharm. 2008;5(6):1003-19.
20. Shah PP, Desai PR, Channer D, Singh M. Enhanced skin permeation using polyarginine modified nanostructured lipid carriers. J Control Release. 2012;161(3):735-45.
21. Shah PP, Desai PR, Patel AR, Singh MS. Skin permeating nanogel for the cutaneous co-delivery of two anti-inflammatory drugs. Biomaterials. 2012;33(5):1607-17.
22. Shah PP, Desai PR, Singh M. Effect of oleic acid modified polymeric bilayered nanoparticles on percutaneous delivery of spantide II and ketoprofen. J Control Release. 2012;158(2):336-45.
23. Desai PR, Shah PP, Patlolla RR, Singh M. Dermal microdialysis technique to evaluate the trafficking of surface-modified lipid nanoparticles upon topical application. Pharm Res-Dordr. 2012;29(9):2587-600.
24. Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res-Dordr. 2008;25(5):999-1022.
25. Bowey K, Neufeld RJ. Systemic and mucosal delivery of drugs within polymeric microparticles produced by spray drying. BioDrugs. 2010;24(6):359-77.
26. Sollohub K, Cal K. Spray drying technique: II. Current applications in pharmaceutical technology. J Pharm Sci. 2010;99(2):587-97.
27. Nekkanti V, Karatgi P, Prabhu R, Pillai R. Solid self-microemulsifying formulation for candesartan cilexetil. Aaps Pharmscitech. 2010;11(1):9-17.
28. Desai PR, Shah PP, Hayden P, Singh M. Investigation of follicular and non-follicular pathways for polyarginine and oleic acid-modified nanoparticles. Pharm Res-Dordr. 2013;30(4):1037-49.
29. Boakye CHA, Doddapaneni R, Shah PP, Patel AR, Godugu C, Safe S, et al. Chemoprevention of skin cancer with 1,1-Bis (3 ′-Indolyl)-1-(Aromatic) methane analog through induction of the orphan nuclear receptor, NR4A2 (Nurr1). Plos One. 2013 8(8).
30. Andey TA, Marepally S, Singh P, Singh M. Knockdown of annexin A2 by liposomal formulation of annexin A2 small hairpin RNA induces apoptosis and inhibits angiogenesis in lung cancer stem cells. Cancer Res. 2013;73(8):3738.
31. Andey T, Patel A, Jackson T, Safe S, Singh M. 1, 1-Bis (3′-indolyl)-1-(p-substitutedphenyl) methane compounds inhibit lung cancer cell and tumor growth in a metastasis model. Eur J Pharm Sci. 2013;50(2):227-41.
32. Andey T, Marepally S, Patel A, Jackson T, Sarkar S, O'Connell M, et al. Cationic lipid guided short-hairpin RNA interference of annexin A2 attenuates tumor growth and metastasis in a mouse lung cancer stem cell model. J Control Release. 2014;184(2):67-78.
33. Godugu C, Patel AR, Doddapaneni R, Somagoni J, Singh M. Approaches to improve the oral bioavailability and effects of novel anticancer drugs berberine and betulinic acid. PLoS One. 2014;9(3), e89919.
34. Faivre L, Gomo C, Mir O, Taieb F, Schoemann-Thomas A, Ropert S, et al. A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma. J Chromatogr B Anal Technol Biomed Life Sci. 2011;879:2345-50.
35. Godugu C, Patel AR, Doddapaneni R, Marepally S, Jackson T, Singh M. Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. J Control Release. 2013;172(1):86-95.
36. Wis̈niewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods. 2009;6(5):359-62.
37. Jablan J, Szalontai G, Jug M. Comparative analysis of zaleplon complexation with cyclodextrins and hydrophilic polymers in solution and in solid state. J Pharm Biomed. 2012;71:35-44.
38. Yuvaraja K, Khanam J. Enhancement of carvedilol solubility by solid dispersion technique using cyclodextrins, water soluble polymers and hydroxyl acid. J Pharm Biomed. 2014;96:10-20.
39. Shelma R, Sharma CP. In vitro cell culture evaluation and in vivo efficacy of amphiphilic chitosan for oral insulin delivery. J Biomed Nanotechnol. 2013;9(2):167-76.
40. Knight LA, Di Nicolantonio F, Whitehouse P, Mercer S, Sharma S, Glaysher S, et al. The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC Cancer. 2004;4:83.
41. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 2002;20:2240-50.
42. Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A. 2005;102:3788-93.
43. Kaur J, Tikoo K. p300/CBP dependent hyperacetylation of histone potentiates anticancer activity of gefitinib nanoparticles. Bioch et Biophy Acta. 1833;2013:1028-40.
44. Ishimaru D, Zuraw L, Ramalingam S, Sengupta TK, Bandyopadhyay S, Reuben A, et al. Mechanism of regulation of bcl-2 mRNA by nucleolin and A + U-rich element-binding factor 1 (AUF1). J Biol Chem. 2010;285:27182-91.
45. Wang LP, Bi J, Yao C, Xu XD, Li XX, Wang SM, et al. Annexin A1 expression and its prognostic significance in human breast cancer. Neoplasma. 2010;57:253-9.
46. Goncalves A, Finetti P, Sabatier R, Gilabert M, Adelaide J, Borg JP, et al. Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Res Treat. 2011;127:273-81.
47. Yamanaka M, Kimura F, Kagata Y, Kondoh N, Asano T, Yamamoto M, et al. BIGH3 is overexpressed in clear cell renal cell carcinoma. Oncol Rep. 2008;19:865-74.
48. Lee TH, Pastorino L, Lu KP. Peptidyl-prolyl cis-trans isomerase Pin1 in ageing, cancer and Alzheimer disease. Exp Rev Mol Med. 2011;13, e21.
49. Jiang X, Yue J, Lu H, Campbell N, Yang Q, Lan S, et al. Inhibition of filamin-A reduces cancer metastatic potential. Int J Biol Sci. 2013;9:67-77.
50. Goplen D, Wang J, Enger PO, Tysnes BB, Terzis AJ, Laerum OD, et al. Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res. 2006;66:9895-902.
51. Wang W, Eddy R, Condeelis J. The cofilin pathway in breast cancer invasion and metastasis. Nat Rev Cancer. 2007;7:429-40.
52. Hwang YJ, Lee SP, Kim SY, Choi YH, Kim MJ, Lee CH, et al. Expression of heat shock protein 60 kDa is upregulated in cervical cancer. Yonsei Med J. 2009;50:399-406.
53. Willis ND, Cox TR, Rahman-Casans SF, Smits K, Przyborski SA, van den Brandt P, et al. Lamin A/C is a risk biomarker in colorectal cancer. PLoS One. 2008;3, e2988.
54. Karlenius TC, Tonissen KF. Thioredoxin and cancer: a role for thioredoxin in all states of tumor oxygenation. Cancers. 2010;2:209-32.
55. Misra A, Pandey C, Sze SK, Thanabalu T. Hypoxia activated EGFR signaling induces epithelial to mesenchymal transition (EMT). PLoS One. 2012;7, e49766.
56. Zhao H, Lo YH, Ma L, Waltz SE, Gray JK, Hung MC, et al. Targeting tyrosine phosphorylation of PCNA inhibits prostate cancer growth. Mol Cancer Ther. 2011;10:29-36.
57. Cox TR, Bird D, Baker AM, Barker HE, Ho MW, Lang G, et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res. 2013;73:1721-32.
58. Sawabu T, Seno H, Kawashima T, Fukuda A, Uenoyama Y, Kawada M, et al. Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway. Mol Carcinog. 2007;46:155-64.
59. Katada K, Tomonaga T, Satoh M, Matsushita K, Tonoike Y, Kodera Y, et al. Plectin promotes migration and invasion of cancer cells and is a novel prognostic marker for head and neck squamous cell carcinoma. J Proteomics. 2012;75:1803-15.
60. Shao R, Bao S, Bai X, Blanchette C, Anderson RM, Dang T, et al. Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cel Biol. 2004;24:3992-4003.
61. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res. 2006;66:3197-204.
62. Ros S, Schulze A. Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases in cancer metabolism. Cancer Metab. 2013;1:8.
63. Goldberg MS, Sharp PA. Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med. 2012;209:217-24.
64. Xie H, Hanai J, Ren JG, Kats L, Burgess K, Bhargava P, et al. Targeting lactate dehydrogenase - a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metab. 2014;19:795-809.
65. Yu H, Xin Y. Down-regulated expressions of PPARgamma and its coactivator PGC-1 are related to gastric carcinogenesis and Lauren's classification in gastric carcinoma. Chin J Cancer Res. 2013;25:704-14.
66. Zhang Y, Ba Y, Liu C, Sun G, Ding L, Gao S, et al. PGC-1alpha induces apoptosis in human epithelial ovarian cancer cells through a PPARgamma-dependent pathway. Cell Res. 2007;17:363-73.
67. Yang L, Chen Y, Cui T, Knosel T, Zhang Q, Albring KF, et al. Desmoplakin acts as a tumor suppressor by inhibition of the Wnt/beta-catenin signaling pathway in human lung cancer. Carcinogenesis. 2012;33:1863-70.
68. Anand S, Honari G, Hasan T, Elson P, Maytin EV. Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo. Clin Cancer Res. 2009;15:3333-43.
69. Zhu B, Lu L, Cai W, Yang X, Li C, Yang Z, et al. Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis. Mol Cancer Ther. 2007;6:3297-306.
70. Kao WT, Lin CY, Lee LT, Lee PP, Hung CC, Lin YS, et al. Investigation of MMP-2 and -9 in a highly invasive A431 tumor cell sub-line selected from a Boyden chamber assay. Anticancer Res. 2008;28:2109-20.